Akeso's Ivonescimab Wins ESMO Late-Breaking Slot for Biliary Cancer Data
Hong Kong – September 21, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.
Phase III biliary tract cancer trial secures Presidential Symposium slot
Overall survival results from the Phase III HARMONi-GI1 trial, comparing ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer, will be delivered as a late-breaking oral presentation (LBA8) on October 25 at 16:30-18:15 in Madrid. The presentation will be given by Jian Zhou of Shanghai during Presidential Symposium II.